Jedd Wolchok received his undergraduate degree from Princeton University and both M.D and Ph.D. from New York University, where he also fulfilled his residency program. He completed his fellowship at MSK and remained on faculty with an appointment in the Melanoma Immunotherapeutics Service.
Jedd Wolchok, MD, PhD is the Lloyd J. Old and Daniel K. Ludwig Chair in Clinical Investigation, Chief of the Melanoma and Immunotherapeutics Service, Director of the Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center with an expertise in the treatment of metastatic melanoma. He has been at the forefront of cancer immunotherapy, as an active clinician scientist exploring immunotherapy and as a principal investigator in several pivotal clinical trials, including the phase III trial that led to the FDA approval of ipilimumab + nivolumab as a treatment for patients with advanced melanoma.
Dr. Wolchok has been recognized for his career throughout the years and has received several of awards including the Melanoma Research Foundation – Humanitarian Award in 2010, the Melanoma International Foundation's Doctor of the Year award in 2012, and the Live, Love, Laugh Foundation and was named the Virginia and Daniel K. Ludwig Chair for Clinical Investigation in 2013. He has been recognized with the American Association for Cancer Research Richard and Hinda Rosenthal Memorial Award, the Giants of Cancer Care in Melanoma Award and received the AICF Prize for Scientific excellence in Medicine. Most recently, he has received the Melvin and Sylvia Griem Lectureship in Molecular and Cellular Oncology; the Alumni Achievement Award in Clinical and Translational Science from NYU and the Alfred Taubman Prize for Excellence in Translational Medical Research.